Vicore Pharma Holding AB (publ) (VICO) - Total Liabilities
Based on the latest financial reports, Vicore Pharma Holding AB (publ) (VICO) has total liabilities worth Skr124.16 Million SEK (≈ $13.36 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Vicore Pharma Holding AB (publ) - Total Liabilities Trend (2012–2025)
This chart illustrates how Vicore Pharma Holding AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See Vicore Pharma Holding AB (publ) (VICO) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Vicore Pharma Holding AB (publ) Competitors by Total Liabilities
The table below lists competitors of Vicore Pharma Holding AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
USANA Health Sciences Inc
NYSE:USNA
|
USA | $144.18 Million |
|
GuangZhou Wahlap Technology Corporation Limited
SHE:301011
|
China | CN¥574.54 Million |
|
Airsculpt Technologies Inc
NASDAQ:AIRS
|
USA | $91.74 Million |
|
Suzhou Yangtze New Materials
SHE:002652
|
China | CN¥195.20 Million |
|
The Star Entertainment Group Limited
F:EE9
|
Germany | €1.07 Billion |
|
Hai An Transport and Stevedoring JSC
VN:HAH
|
Vietnam | ₫3.32 Trillion |
|
Semler Scientific Inc
NASDAQ:SMLR
|
USA | $136.93 Million |
|
Shinsegae Inte
KO:031430
|
Korea | ₩567.22 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Vicore Pharma Holding AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Vicore Pharma Holding AB (publ).
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vicore Pharma Holding AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vicore Pharma Holding AB (publ) (2012–2025)
The table below shows the annual total liabilities of Vicore Pharma Holding AB (publ) from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr124.16 Million ≈ $13.36 Million |
+68.28% |
| 2024-12-31 | Skr73.78 Million ≈ $7.94 Million |
+73.81% |
| 2023-12-31 | Skr42.45 Million ≈ $4.57 Million |
-13.23% |
| 2022-12-31 | Skr48.92 Million ≈ $5.27 Million |
-27.90% |
| 2021-12-31 | Skr67.85 Million ≈ $7.30 Million |
+30.48% |
| 2020-12-31 | Skr52.00 Million ≈ $5.60 Million |
+166.53% |
| 2019-12-31 | Skr19.51 Million ≈ $2.10 Million |
+20.71% |
| 2018-12-31 | Skr16.16 Million ≈ $1.74 Million |
+146.44% |
| 2017-12-31 | Skr6.56 Million ≈ $705.85K |
+8.36% |
| 2016-12-31 | Skr6.05 Million ≈ $651.40K |
-17.03% |
| 2015-12-31 | Skr7.29 Million ≈ $785.06K |
+28.61% |
| 2014-12-31 | Skr5.67 Million ≈ $610.40K |
-48.30% |
| 2013-12-31 | Skr10.97 Million ≈ $1.18 Million |
+90651.92% |
| 2012-12-31 | Skr12.09K ≈ $1.30K |
-- |
About Vicore Pharma Holding AB (publ)
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial f… Read more